Voriconazole therapeutic drug monitoring
Voriconazole therapeutic drug monitoring
复制标题
DOI：
10.1128/aac.50.4.1570-1572.2006
复制
发表时间：
2006-04-01
影响因子：
4.9
通讯作者：
Andes, D
中科院分区：
文献类型：
--
作者：
Smith, J;Safdar, N;Andes, D
我们报告了28例因疾病进展或毒性而接受伏立康唑监测的患者。药物浓度与病情进展有相关性（P < 0.025）。在浓度高于2.05 μ g/ml的10/10例患者中观察到有利的反应，而在浓度低于2.05 μ g/ml的44%（n = 18）的患者中观察到疾病进展。
We report on 28 patients who underwent voriconazole monitoring because of disease progression or toxicity. A relationship (P < 0.025) between disease progression and drug concentration was detected. Favorable responses were observed in 10/10 patients with concentrations above 2.05 mu g/ml, while disease progressed in 44% (n = 18) of patients with concentrations below 2.05 mu g/ml.